Brian Francis, MD
Ophthalmology · Fountain Valley, CANPI 1427118348
Payments from drug & device makers
Across 330 payments — averaging $866.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$56K
- Iridex Corporation$53K
- Aerie Pharmaceuticals, Inc.$42K
- Beaver-visitec International, Inc.$38K
- Bausch & Lomb Americas Inc.$35K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$30K
- plus $33K from 19 others
Across 1 payment — averaging $5.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$5
What the payments were for
- Consulting fees$87,78636%
- Speaking & faculty fees$149,56261%
- Travel & lodging$2,2701%
- Food & beverage$7,2173%
- Education$2800%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 60 | $55,656 |
| Iridex Corporation | 21 | $52,750 |
| Aerie Pharmaceuticals, Inc. | 38 | $41,652 |
| Beaver-visitec International, Inc. | 8 | $38,070 |
| Bausch & Lomb Americas Inc. | 40 | $35,140 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 44 | $29,611 |
| Alcon | 38 | $12,909 |
| Microsurgical Technology, Inc. | 1 | $9,050 |
| Ivantis, Inc | 7 | $4,711 |
| Thea Pharma Inc. | 25 | $4,328 |
| NEW World Medical,inc. | 7 | $554 |
| Glaukos Corporation | 1 | $500 |
| Sun Pharmaceutical Industries Inc. | 8 | $222 |
| Amgen | 6 | $196 |
| Novartis | 7 | $160 |
| Merz Pharmaceuticals, LLC | 3 | $83 |
| Oyster Point Pharma, Inc. | 4 | $83 |
| Shire North American Group Inc | 3 | $53 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $46 |
| Nova Eye, Inc. | 1 | $45 |
| Harrow Eye, LLC | 2 | $45 |
| Rayner Intraocular Lenses Limited | 1 | $24 |
| Rxsight Inc | 1 | $23 |
| Eyevance Pharmaceuticals LLC | 1 | $21 |
| Sight Sciences, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYZULTA$63,184
- Rhopressa$51,252
- Rocklatan$51,252
- IYUZEH$3,900
- DURYSTA$3,500
- Hydrus Microstent$3,286
- LUMIGAN$3,025
- XEN$2,916
- COMBIGAN$2,025
- ALPHAGAN P$2,025
- Hydrus$1,500
- iStent inject Trabecular Micro-Bypass Stent System$500
- Ahmed Glaucoma Valve$299
- Kahook Dual Blade$299
- Clearpath$190
- Streamline$190
- Via360$190
How this compares
$285,952 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 672 | $371,415 |
| VyzultaLatanoprostene Bunod | 238 | $131,322 |
| RocklatanNetarsudil Mesylat/Latanoprost | 198 | $128,913 |
| RhopressaNetarsudil Mesylate | 187 | $106,945 |
| RestasisCyclosporine | 89 | $89,142 |
| Alphagan PBrimonidine Tartrate | 157 | $76,668 |
| CombiganBrimonidine Tartrate/Timolol | 116 | $50,779 |
| Travoprost | 222 | $42,947 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 112 | $37,412 |
| Travatan ZTravoprost | 66 | $37,226 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 168 | $31,798 |
| Brimonidine Tartrate | 360 | $26,791 |
| XiidraLifitegrast | 23 | $26,572 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 156 | $25,144 |
| AzoptBrinzolamide | 55 | $25,129 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Alphagan P, Combigan | $55,656 | $588,0041,034 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $41,652 | $235,858385 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $35,140 | $157,894261 claims |
| AlconSimbrinza, Azopt | $12,909 | $62,541167 claims |
| NovartisTravatan Z | $160 | $37,22666 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Loteprednol Etabonate | $29,611 | $18,69198 claims |
| Thea Pharma Inc.Iyuzeh | $4,328 | $12,59731 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Fountain Valley
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
- Peter WinArcadia$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.